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OBJECTIVE: Heart failure is a progressive and debilitating disease. Intracoronary sarcoplasmic reticulum calcium-
ATPase gene therapy may improve the function of cardiac muscle cells. This study aimed to test the hypothesis
that intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy can improve outcomes and reduce the
number of recurrent and terminal events in advanced heart failure patients with reduced ejection fraction.
METHODS: A total of 768 heart failure patients with reduced ejection fraction and New York Heart Association
classification II to IV were included in this prospective cohort study. Patients either underwent intracoronary
sarcoplasmic reticulum calcium-ATPase gene therapy (CA group, n=384) or received oral placebo (PA group;
n=384). Data regarding recurrent and terminal event(s), treatment-emergent adverse effects, and outcome
measures were collected and analyzed.
RESULTS: After a follow-up period of 18 months, intracoronary sarcoplasmic reticulum calcium-ATPase gene
therapy reduced the number of hospital admissions (p=0.001), ambulatory treatments (p=0.0004), and deaths
(p=0.024). Additionally, intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy improved the left
ventricular ejection fraction (po0.0001) and Kansas City Cardiomyopathy Questionnaire score (po0.0001). The
number of recurrent and terminal events/patients were higher in the PA group than in the CA group after
the follow-up period of 18 months (p=0.015). The effect of the intracoronary sarcoplasmic reticulum calcium-
ATPase gene therapy was independent of the confounding variables. No new arrhythmias were reported in
the CA group.
CONCLUSIONS: Intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy reduces the number of
recurrent and terminal events and improves the clinical course of advanced heart failure patients with reduced
ejection fraction.
KEYWORDS: Cardiac Events; Ejection Fraction; Heart Failure; Intracoronary Delivery; Sarcoplasmic Reticulum
calcium-ATPase Gene Therapy.
’ INTRODUCTION
Heart failure is a progressive and debilitating disease (1). It
is associated with inadequate contractility of the heart (2)
due to abnormal calcium cycling (3). Morbidity and morta-
lity in heart failure patients are high (4,5). Drugs for heart
failure only slow down the progression of the disease but
do not cure the disease (6). Calcium-ATPase deficiency is
generally associated with the progression of heart failure
(7,8). During diastole, the sarcoplasmic reticulum calcium-
ATPase regulates contraction and relaxation of cardiac
muscle cells by transporting calcium from the cytosol into
the sarcoplasmic reticulum (9). Gene therapy restores the
function of the heart as a pump (2). If calcium-ATPase
deficiency is corrected, the function of the cardiac muscle
cells may be improved in heart failure patients (7).
An experimental model (7,8), a phase 2 trial involving a
high-dose of sarcoplasmic reticulum calcium-ATPase gene
therapy in advanced heart failure patients (10), and a rando-
mized trial (3) involving the use of gene therapy for the
treatment of cardiac disease have confirmed the hypothesis
that sarcoplasmic reticulum calcium-ATPase gene transfer
improves survival and the performance of cardiac muscle
cells in heart failure conditions. However, a phase 2b trial
involving high-risk ambulatory patients with heart failure (9)
revealed that high-dose intracoronary sarcoplasmic reticulumDOI: 10.6061/clinics/2020/e1530
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calcium-ATPase gene therapy does not improve cardiac
muscle cell performance in heart failure patients. Thus, the
favorable effect of targeted intracoronary sarcoplasmic reticu-
lum calcium-ATPase gene therapy in heart failure patients has
not been thoroughly investigated.
The aim of this study is to test the hypothesis that intra-
coronary sarcoplasmic reticulum calcium-ATPase gene ther-
apy can improve outcomes and reduce the number of
recurrent and terminal events in advanced heart failure
patients with reduced ejection fraction.
’ MATERIALS AND METHODS
Ethics consideration and consent to participate
The designed protocol (SRHS/CL/12/15 dated December
5th 2015) of the established study was approved by the
review board of Second Rehabilitation Hospital of Shanghai.
The study was reported according to the laws of China,
strengthening the reporting of observational studies in
epidemiology (STROBE) statement, and the 2008 Helsinki
Declaration. An informed consent form was signed by all
enrolled patients regarding the publication of data on patho-
logy and interventions, including personal data and images
(if any), in all formats (hard and/or electronic).
Inclusion criteria
Patients aged 18 to 80 years, who had experienced chronic
heart failure as per the 2016 European Society of Cardiology
(ESC) Guidelines (11) (confirmed by left ventricular angio-
graphy for ejection fraction), and had been undergoing
medical treatment for at least one month in the Second
Rehabilitation Hospital of Shanghai, Shanghai, China, were
considered for the study. Among these patients, only those
with the New York Heart Association (NYHA) heart func-
tional classification II to IV (for ischemic or non-ischemic
etiology) and a left ventricular ejection fraction 35% or less
were included in the analysis. Heart failure patients with
undetectable neutralizing antibodies who could not block
vector entry of adeno-associated viruses 1 into the target cells
were only included in the study.
Exclusion criteria
Patients aged above 80 years, pregnant females, those who
had undergone cardiac surgery, and those who had under-
gone either percutaneous coronary intervention, acute heart
failure treatment (positive inotropes, intravenous vasodila-
tors, or diuretics), or valvuloplasty were excluded from the
study. Restrictive cardiomyopathic patients, obstructive car-
diomyopathic patients, and patients who had amyloidosis
(confirmed by blood and urine tests, biopsies of belly fat, and
imaging methods), acute myocarditis, infiltrative cardiom-
yopathy, pericardial disease, thyroid disease, abnormal liver
function, anemia, thrombocytopenia, carcinoma, sarcoma,
and/or cancer were also excluded from the study.
Sample size calculation
The sample size was calculated using OpenEpi (Epide-
miologic Statistics for Public Health, USA) at a power of 80%.
The sample size for both cohorts was calculated as 384.
Cohorts
Patients who received intracoronary 11013 DNase-
resistant particles of adeno-associated virus 1 sarcoplasmic
reticulum calcium-ATPase (CA) (Luxturna; Sparks Thera-
peutics, Philadelphia, PA, USA) were assigned to the CA
group (n=384) and patients who received oral placebo
(Cebocap, Forte Pharmaceutical, Hyderabad, India) were
assigned to the PA (placebo group; n=384) (9). Data on the
function of the liver, kidney, and other vital organs were
reviewed before the administration of calcium-ATPase.
Recurrent and terminal events during a follow-up
period of 18 months
The number of hospital admissions due to heart failure
and the number of ambulatory treatments for worsening
conditions were acquired. Information regarding all causes
of death, heart transplantations performed, and the use of
a mechanical ventilation system were also collected (6).
Additionally, data on the incidences and severity of inter-
ventions-emergent adverse events and the number of deaths
(cardiovascular-related) were collected (9).
Outcome measures
We collected data on blood pressure, changes in the
NYHA functional class of the heart, Kansas City Cardiomyo-
pathy Questionnaire (KCCQ; 23-item questionnaire; the
score ranged from 0 to 100) score (12), exercise ability (6-
min walk test; comparison was made with patients who had
no neuromuscular, orthopedic, or rheumatologic abnormal-
ity, and were able to walk 300–400 m in 6 min (6)), creatinine
level (10), and N-terminal pro-B-type natriuretic peptide
(NT-proBNP) at baseline and at 1, 3, 6, 10, and 18 months
after interventions. Endomyocardial biopsy was performed
after 18 months of intervention to evaluate the development
of new heart failure and/or arrhythmias (13).
Outcome measures were collected by physicians and the
nursing staff of the institute(s) (all personnel had a minimum
of three years of experience). For patients who died during
the follow-up period, the last reported data were used for
analysis.
Safety
All new arrhythmias found during the 18-month follow-
up period were recorded.
Statistical analysis
For statistical analysis, InStat, 3.1 Window, GraphPad, San
Diego, CA, USA was used. For ordinal data, the Chi-square
Independence test (4) was used for statistical analysis while
the one-way analysis of variance (ANOVA) (14) was used
to analyze continuous variables. Logistic regression ana-
lysis was performed to evaluate the risk factors for recurrent
and terminal events during the 18-month follow-up period.
All results were considered significant at a 95% confidence
level.
’ RESULTS
Clinical characteristics
Among the enrolled patients, 80% were males and 99%
were Han Chinese. Additionally, most of the patients had
NYHA heart functional class III. The other clinical character-
istics of the patients are presented in Table 1. At baseline,
both groups had the same demographical and clinical
characteristics (p40.05 for all).
2
Sarcoplasmic Reticulum Calcium-ATPase Gene Therapy
Zhang J et al.
CLINICS 2020;75:e1530
Recurrent and terminal events
After a follow-up period of 18 months, intracoronary sarco-
plasmic reticulum calcium-ATPase gene therapy reduced the
number of hospital admissions (p=0.001), ambulatory treat-
ments (p=0.0004), and deaths (p=0.024) but was not successful
in reducing the number of heart transplantations (p=0.576) and
mechanical ventilation incidences (p=0.864, Figure 1).
Outcome measures
After a follow-up period of 18 months, intracoronary
sarcoplasmic reticulum calcium-ATPase gene therapy imp-
roved the heart function (p=0.009), left ventricular ejection
fraction (po0.0001), KCCQ score (po0.0001), systolic blood
pressure (po0.0001), and performance in the 6-min walk
test (p=0.047). However, intracoronary sarcoplasmic reti-
culum calcium-ATPase gene therapy failed to reduce the
NT-proBNP (p=0.482) and serum creatinine (p=0.822,
Table 2) levels.
Age (p=0.048), NT-proBNP (p=0.046), and placebo treat-
ment (p=0.021) were associated with recurrent and terminal
events during the 18-month follow-up period and the effect
of the intracoronary sarcoplasmic reticulum calcium-ATPase
gene therapy was independent of the confounding variables
(Table 3). Moreover, cumulative recurrent and terminal
events/patients were higher in the PA group than in the
CA group during the 18-month follow-up period (p=0.015,
Figure 2).
Table 1 - Demographic and clinical characteristics of the enrolled patients.
Characteristics
Groups
Comparison
between
groups
CA PA
Heart failure patients enrolled in the cohort 384 384
Treatment Intracoronary sarcoplasmic
reticulum Calcium-ATPase
gene therapy
Oral placebo
p-value
Age (years) Minimum 18 18 0.272
Maximum 80 80
Mean ± SD 59.12±11.45 60.11±13.45
Gender Male 308 (80) 306 (80) 0.928
Female 76 (20) 78 (20)
Ethnicity Han Chinese 380 (99) 379 (98.7) 0.930
Tibetan 1 (0.3) 1 (0.3)
Mongolian 3 (0.7) 4 (1)
6-min walk test (m) 315.15±49.47 321.52±61.52 0.114
Left ventricular ejection fraction (%) 24.12±4.15 24.92±7.15 0.058
NYHA heart functional classification II 75 (20) 74 (19) 0.996
III 301 (78) 302 (79)
IV 8 (2) 8 (2)
KCCQ score 60.12±3.15 59.68±4.01 0.09
NT-proBNP (pg/mL) 1511±102 1499±99 0.099
Cause of heart failure Idiopathic 160 (42) 162 (42) 0.970
Ischemic 194 (50) 191 (50)
Hereditary 4 (1) 5 (1)
Hypertension 18 (5) 20 (5)
Peripartum 8 (2) 6 (2)
Abnormal renal function 8 (2) 9 (2) 0.806
Chronic obstructive pulmonary disease 15 (4) 11 (3) 0.550
Creatinine (mg/dL) 1.81±0.61 1.79±0.59 0.644
Systolic blood pressure (mmHg) 132±6 133±8 0.051
Medical treatment Special beta-blockers 155 (41) 165 (43) 0.801
Angiotensin-converting enzyme
inhibitors
101 (26) 99 (26)
Angiotensin II receptor antagonist 85 (22) 75 (19)
Aldosterone receptor antagonists 43 (11) 45 (12)
NYHA: New York Heart Association.
KCCQ: Kansas City Cardiomyopathy Questionnaire (range: 0 to 100).
NT-proBNP: N-terminal pro-B-type natriuretic peptide (NT-proBNP level o1600 pg/mL was considered as normal).
Ordinal data are shown as frequency (percentage) and continuous variable are shown as mean ± SD.
The Chi-square Independence test for ordinal data and one-way ANOVA for continuous variables were used for statistical analyses.
A p-value o0.05 was considered significant.
Figure 1 - Recurrent and terminal events after a follow-up
period of 18 months. The chi-square test of independence
was performed between the two groups. A p-value o0.05 was
considered significant. *A significant fewer values reported
than the placebo group.
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Safety
In the CA group, endomyocardial biopsies performed after
the 18-month follow-up period, revealed no new arrhythmias
or treatment-emergent adverse effects.
’ DISCUSSION
In the present study, intracoronary sarcoplasmic reticulum
calcium-ATPase gene therapy reduced the number of recur-
rent and terminal events. In heart failure patients, a decrease
in sarcoplasmic reticulum calcium-ATPase activity results
in reduced calcium uptake during relaxation (6), which is
associated with depressed calcium homeostasis and reduced
cardiomyocyte function (9) due to the reduction in the
contractile function of the heart (5). Recurrent and terminal
events are frequent during the clinical course of patients
with cardiac disease (15) due to disturbance of the immune
pathway and the short duration of transgene expression (16),
which leads to increases in the financial burden of patients
(17). The correction of these abnormalities using intracor-
onary DNase-resistant particles of adeno-associated virus 1
can improve cardiac function and the survival rate (8,18) by
improving vascular reactivity and coronary flow (19). Addi-
tionally, intracoronary calcium-ATPase transfer decreases
the number of ventricular arrhythmias and improves the
arrhythmogenic substrate and the factors that trigger it by
Table 2 - Outcome measures for cardiac function reported after a follow-up period of 18 months.
Characteristics
Groups
Comparison
between
groups at EL
CA PA
Treatment
Intracoronary sarcoplasmic reticulum
Calcium-ATPase gene therapy
Oral placebo
Level BL EL SA BL EL SA
Patients enrolled in the cohort 384 384 p-value 384 384 p-value p-value
NYHA heart functional
classification
II 75 (20) 105 (27) 0.023 74 (19) 73 (19) 0.891 0.009
III 301 (78) 275 (72) 302 (79) 301 (78)
IV 8 (2) 4 (1) 8 (2) 10 (3)
6-min walk test (m) 315.15±49.47 325.27±51.52 0.006 321.52±61.52 323.47±65.47* 0.671 0.047
Left ventricular ejection fraction (%) 24.12±4.15 29.35±7.45 o0.0001 24.92±7.15 25.12±7.65* 0.708 o0.0001
KCCQ score 60.12±3.15 65.45±5.46 o0.0001 59.68±4.01 60.01±4.45* 0.281 o0.0001
yNT-proBNP (pg/mL) 1511±102 1501±99* 0.168 1499±99 1496±98* 0.673 0.482
Creatinine (mg/dL) 1.81±0.61 1.79±0.62* 0.652 1.79±0.59 1.78±0.6* 0.817 0.822
Systolic blood pressure (mmHg) 132±6 128±5 o0.0001 133±8 132±6* 0.051 o0.0001
BL: At the time of enrollment.
EL: After a follow-up period of 18 months.
SA: Statistical analysis between BL and EL.
Ordinal data are shown as frequency (percentage) and continuous variable are shown as mean ± SD.
The Chi-square Independence test for ordinal data and one-way ANOVA for continuous variables were used for statistical analyses.
A p-value o0.05 was considered significant.
If the patient died during the follow-up period, the last reported data were used for analysis.
*Insignificant difference with respect to BL.
yo1600 pg/mL was considered normal.
Table 3 - The influence of risk factors on recurrent and terminal events after a follow-up period of 18 months.
Heart failure patients included in the analysis 768
Characteristics Risk ratio 95% CI p-value
*Age (years) 4.05 0.75–4.61 0.048
Gender 0.56 0.42–1.12 0.82
Ethnicity 0.54 0.53–1.15 0.63
6-min walk test (m) 0.68 0.54–1.17 0.65
Left ventricular ejection fraction (%) 0.42 0.67–1.19 0.68
NYHA heart functional classification 0.46 0.56–1.09 0.67
KCCQ score 0.52 0.52–1.08 0.56
*NT-proBNP (pg/mL) 3.87 0.81–4.22 0.046
Cause of heart failure 0.54 0.82–1.12 0.56
Abnormal renal function 0.55 0.63–1.15 0.63
Chronic obstructive pulmonary disease 0.63 0.68–1.27 0.59
Creatinine (mg/dL) 0.71 0.56–1.41 0.63
Treatment Calcium-ATPase 0.82 0.51–0.98 0.82
*Placebo 6.52 1.12–6.12 0.021
NYHA: New York Heart Association.
KCCQ: Kansas City Cardiomyopathy Questionnaire (range from 0 to 100).
NT-proBNP: N-terminal pro-B-type natriuretic peptide (NT-proBNP level o1600 pg/mL was considered as normal).
A risk ratio 41 and a p-value o0.05 were considered significant.
A p-value o0.05 was considered significant.
*Significant factor responsible for recurrent and terminal events after a follow-up period of 18 months.
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entering the cardiac cells, where high transduction efficiency
is necessary. Moreover, entering of the adeno-associated
viruses 1 in cardiac cells tropism provides homogeneous
cardiac myocyte transduction (3). The results of the analysis
were consistent with the results of previous experimental
studies (16,18), pilot studies (3,9), and a phase 2 trial (10),
but were not consistent with the results of the phase 2b
trial (9). The results of the current study showed that the
intracoronary DNase-resistant particles of adeno-associated
virus 1 sarcoplasmic reticulum calcium-ATPase may
improve the clinical course of heart failure patients with
reduced ejection fraction.
Intracoronary sarcoplasmic reticulum calcium-ATPase gene
therapy improved the NYHA class, performance during the
6-min walk test, left ventricular ejection fraction, KCCQ score,
and systolic blood pressure. The improvement in the KCCQ
score and 6-min walk test would result in an increase in
the ability of patients to perform physical activities, which
would result in the improvement of the NYHA class (20).
Intracoronary sarcoplasmic reticulum calcium-ATPase gene
therapy significantly inhibits left ventricular dilation, which
restores systolic functions of the heart (21). The results of the
analysis were consistent with the results of the phase 2 trial
(10) and experimental studies (16,22). The positive results
regarding outcome measures showed that intracoronary
sarcoplasmic reticulum calcium-ATPase gene therapy may
be beneficial to heart failure patients with reduced ejection
fraction.
Intracoronary sarcoplasmic reticulum calcium-ATPase
gene therapy failed to reduce the NT-proBNP (p=0.482) and
creatinine (p=0.822) levels. An NT-proBNP level higher than
1600 pg/mL is responsible for recurrent events (6). The
results of the analysis were consistent with the results of
another study (9). NT-proBNP released as a result of targets
not achieved by intracoronary sarcoplasmic reticulum
calcium-ATPase gene therapy (23). In addition, it is well
known that the hydrosaline retention state present during
heart failure is related not only to the hemodynamic
phenomenon due to the heart pumping failure but also as
a result of various neurohumoral mechanisms that maintain
a reduced glomerular filtration rate, which would remain
constant regardless of the improvement in pump function
after intracoronary sarcoplasmic reticulum calcium-ATPase
gene therapy (24). A negative outcome may slow down, but
not deter, further research. These negative results need to be
addressed in future randomized trials.
Intracoronary sarcoplasmic reticulum calcium-ATPase
gene therapy improved the clinical course of the enrolled
patients without any treatment-emergent adverse effects.
Our results are consistent with those of published studies
(3,9,10). Our positive results show that intracoronary sarco-
plasmic reticulum calcium-ATPase gene therapy is safe and
promising.
In this study, gene therapy was performed via intracor-
onary delivery. The percutaneous, cardiac-perfusion circuit
enhances the uptake of the gene by cardiomyocytes (16).
However, intracoronary delivery is simple, practical, and also
enhances uptake of the gene (5). We recommend intracoronary
delivery for gene therapy for optimal effect.
In this study, we reported recurrent and terminal events
simultaneously. Each recurrent event in patients increases
the risk of additional recurrent and terminal events (25). For
example, the mortality rate is higher after the fourth hospi-
talization compared to that after the first hospitalization (6).
Thus, to avoid bias, we evaluated recurrent and terminal
events simultaneously.
One limitation of the study is its prospective nature and
the lack of a randomized trial. If a patient died during the
follow-up period, the last reported data were used for analy-
sis. This increases the possibility of the occurrence of bias.
We did not evaluate the bias between coronary intervention
and oral administration.
’ CONCLUSION
Intracoronary sarcoplasmic reticulum calcium-ATPase
gene therapy reduces the number of recurrent and terminal
events and improves the clinical course of advanced heart
failure patients with reduced ejection fraction.
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